Clinical trial
PROACT - Pre-Operative Arimidex Compared To Tamoxifen
NCT00232661 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00232661 |
|---|---|
| Title | PROACT - Pre-Operative Arimidex Compared To Tamoxifen |
| Official title | A Randomised, Double-blind, Study Comparing ARIMIDEX™ With NOLVADEX™ as Neo-adjuvant and Adjuvant Treatment in Post-menopausal Women With Large Operable (T2 (≥3cm), T3, N0-2, M0) or Potentially-operable, Locally Advanced (T4b, N0-2, M0), ER+ and/or PR+ Breast Cancer. |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | ARIMIDEX (anastrazole), NOLVADEX (tamoxifen) |
| Enrollment | 452 |
| Start date | Aug 1, 2000 |
| Primary completion | Jan 1, 2003 |
| Completion | Dec 1, 2007 |
| First posted | Oct 5, 2005 |
| Last update posted | Feb 3, 2010 |
| Countries | Belgium, Brazil, Canada, Czechia, France, Hungary, Italy, Japan, Netherlands, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: